Evidence map›Paper›PMID 42580866›Full record

ArticleChemMedChem2026

Exploration of Nirmatrelvir Derivatives as Optimized SARS-CoV-2 Antivirals.

Yugendar R Alugubelli, Veerabhadra R Vulupala, Kai S Yang, Kaustav Khatua, Lauren R Blankenship, Sathish Kumar, Demonta Coleman, Xuejiao Guo, Zhi Zachery Geng, Chia-Chuan D Cho and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ChemMedChem, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Yugendar R AlugubelliTexas A&M Drug Discovery Center, Department of Chemistry, College of Arts and Sciences, Texas A&M University, College Station, Texas, USA.
Veerabhadra R VulupalaTexas A&M Drug Discovery Center, Department of Chemistry, College of Arts and Sciences, Texas A&M University, College Station, Texas, USA.ORCID https://orcid.org/0000-0002-6224-5674
Kai S YangTexas A&M Drug Discovery Center, Department of Chemistry, College of Arts and Sciences, Texas A&M University, College Station, Texas, USA.
Kaustav KhatuaTexas A&M Drug Discovery Center, Department of Chemistry, College of Arts and Sciences, Texas A&M University, College Station, Texas, USA.
Lauren R BlankenshipTexas A&M Drug Discovery Center, Department of Chemistry, College of Arts and Sciences, Texas A&M University, College Station, Texas, USA.
Sathish KumarDepartment of Biology, College of Arts and Sciences, Texas A&M University, College Station, Texas, USA.
Demonta ColemanTexas A&M Drug Discovery Center, Department of Chemistry, College of Arts and Sciences, Texas A&M University, College Station, Texas, USA.ORCID https://orcid.org/0000-0002-5806-1813
Xuejiao GuoTexas A&M Drug Discovery Center, Department of Chemistry, College of Arts and Sciences, Texas A&M University, College Station, Texas, USA.
Zhi Zachery GengTexas A&M Drug Discovery Center, Department of Chemistry, College of Arts and Sciences, Texas A&M University, College Station, Texas, USA.ORCID https://orcid.org/0000-0002-0790-1595
Chia-Chuan D ChoTexas A&M Drug Discovery Center, Department of Chemistry, College of Arts and Sciences, Texas A&M University, College Station, Texas, USA.
Banumathi SankaranMolecular Biophysics and Integrated Bioimaging, Berkeley Center for Structural Biology, Laurence Berkeley National Laboratory, Berkeley, California, USA.
Benjamin W NeumanDepartment of Biology, College of Arts and Sciences, Texas A&M University, College Station, Texas, USA.ORCID https://orcid.org/0000-0003-1240-8954
Shiqing XuTexas A&M Drug Discovery Center, Department of Chemistry, College of Arts and Sciences, Texas A&M University, College Station, Texas, USA.ORCID https://orcid.org/0000-0001-6260-9290
Wenshe Ray LiuTexas A&M Drug Discovery Center, Department of Chemistry, College of Arts and Sciences, Texas A&M University, College Station, Texas, USA.ORCID https://orcid.org/0000-0002-7078-6534

Funding

User Training and OutreachP30GM124169 · NIGMS · UNIVERSITY OF CALIF-LAWRENC BERKELEY LAB · PI Gregory L Hura · 2017 to 2026
$28.6M
Use of the Noncanonical Amino Acid Mutagenesis Technique in Combination with Other Approaches to Study Functions of Posttranslational Lysine Modifications in ProteinsR35GM145351 · NIGMS · TEXAS A&M UNIVERSITY · PI Wenshe Ray Liu · 2022 to 2026
$2.6M
Development of fluorogenic and chemiluminogenic main protease substrates for cellular and in vivo imaging of SARS-CoV-2R21EB032983 · NIBIB · TEXAS A&M UNIVERSITY · PI LIU, WENSHE RAY · 2022 to 2023
$411k
The Development of Reversible Covalent PROTAC Technology as a New Anti-COVID-19 StrategyR21AI164088 · NIAID · TEXAS A&M UNIVERSITY · PI XU, SHIQING · 2021 to 2022
$406k
Cancer Prevention and Research Institute of Texas RP210043NIAID NIH HHS R21 AI164088NIBIB NIH HHS R21 EB032983NIGMS NIH HHS P30 GM124169NIGMS NIH HHS R35 GM145351Office of Extramural Research, National Institutes of Health F31CA26883Office of Extramural Research, National Institutes of Health P30GM124169Office of Extramural Research, National Institutes of Health R21AI164088Office of Extramural Research, National Institutes of Health R21EB032983Office of Extramural Research, National Institutes of Health R35GM145351U.S. Department of Defense DE-AC02-05CH11231
6 · The paper itself

Abstract

Nirmatrelvir (NMV) is a SARS-CoV-2 antiviral component of the approved COVID-19 therapeutic Paxlovid. It is a reversible covalent inhibitor of SARS-CoV-2 main protease (M

Indexed as

Antiviral AgentsIndolesProtease InhibitorsSARS-CoV-2Azabicyclo CompoundsCatalytic DomainCoronavirus 3C ProteasesCrystallography, X-RayHumansPyrrolidinonesStructure-Activity RelationshipAntiviral AgentsAzabicyclo CompoundsCoronavirus 3C ProteasesIndolesnirmatrelvirProtease InhibitorsPyrrolidinonescovalent inhibitorCOVID‐19main proteasenirmatrelvirSARS‐CoV‐2

Identifiers

PMID42580866
PMCPMC13461302

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.